OPIANT PHARMACEUTICALS, INC.
Healthcare · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | |
|---|---|---|---|---|---|---|
| Revenue | $40.7M | $27.4M | $40.5M | $14.0M | $18.4M | $9.9M |
| Operating income | $5.2M | −$2.2M | $10.9M | −$21.2M | $7.1M | −$7.7M |
| Net income | $3.0M | −$1.9M | $11.6M | −$21.2M | $6.6M | −$7.8M |
| Total assets | $70.4M | $60.6M | $40.3M | $29.4M | $10.8M | $1.9M |
| Total liabilities | $23.6M | $25.1M | $5.9M | $12.5M | $6.5M | $6.6M |
| Equity | $46.8M | $35.5M | $34.4M | $16.9M | $13.0M | −$4.7M |
| EPS (diluted) | $0.51 | $-0.44 | $2.17 | $-7.10 | $2.94 | $-4.09 |
| Shares out. | 4.3M | 4.2M | 3.9M | 3.8M | 2.0M | 2.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2021- Operating margin
- 12.7%
- Net margin
- 7.4%
- Return on equity
- 6.4%
- Return on assets
- 4.3%
- Return on capital (ROCE)
- 8.1%
- Liabilities / assets
- 33.5%
- Debt / equity
- 0.50×
- Book value / share
- $10.91
- Revenue growth (YoY)
- 48.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2021- Altman Z″ (distress)
- 5.53safe
- Accruals / assets
- 1.5%clean
- Piotroski F-Score
- 7/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 6 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating margin is positive
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Dec 14, 2012
- NT 10-Kmissed a reporting deadline ↗Nov 1, 2010
- NT 10-Qmissed a reporting deadline ↗Dec 16, 2009
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Silver Gabrielle AlisonDirector | Mar 2, 2023 | D | 21,343 | $20.00 |
| Collard Craig ADirector | Mar 2, 2023 | D | 53,822 | $20.00 |
| Ruth Matthew R.Officer — Chief Commercial Officer | Mar 2, 2023 | D | 19,250 | $20.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsMar 2, 2023
- Shareholder voteMar 1, 2023
- Director / officer changeFeb 27, 2023
- Other material eventFeb 7, 2023
- Director / officer changeJan 9, 2023
- Entered a material agreement · Terminated a material agreement · New financial obligationNov 15, 2022
- Results of operationsNov 14, 2022
- Shareholder voteJun 14, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.